The Dana-Farber/Boston Children’s Cancer and Blood Disorders Center invites applications from early-career pediatric oncologists to join our Pediatric Neuro-oncology Program. The appointee will assume a faculty position at Harvard Medical School at the rank of Assistant or Associate Professor. He or she will become a member of the neuro-oncology faculty group, which includes clinicians, clinician-researchers and lab-based physician-scientists. Outstanding applicants will be BC/BE in Pediatric Hematology/Oncology with additional experience and/or fellowship in Neuro-Oncology. This clinical position will allow the faculty member to pursue significant non-clinical time in clinical research, program-building activities, quality/safety or other academic interests. Approximately 120+ new brain tumor patients are seen each year at DF/BCH. Dana-Farber Cancer Institute is a member of the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and the Children’s Oncology Group (COG) Phase I consortium. Our Neuro-oncology Program is internationally recognized for providing outstanding, multidisciplinary care to children with brain tumors, conducting investigator-initiated, consortium and industry-sponsored innovative clinical trials and is committed to training pediatric oncologists and other experts in the care of these patients. The program also collaborates closely with the multitude of basic and translational research labs in the greater Boston biomedical research community to bring new ideas to the treatment of children with brain tumors. The Neuro-oncology program clinical faculty group also partners in research with multiple subspecialists in radiation oncology, neurosurgery, neurology, neuroradiology and pathology at Boston Children’s Hospital, Brigham’s and Women’s Hospital, and with the Dana-Farber/Boston Children’s Hospital pediatric cancer program in Experimental Therapeutics.
The Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has a faculty numbering more than 100, with exceptional research and clinical programs in non-malignant hematology, hematologic malignancies, solid tumors, and neuro-oncology.
The position will be based at the Dana-Farber Cancer Institute (an NCI-designated Comprehensive Cancer Center). Salary offered will be consistent with fair market rate and commensurate with experience.
Interested candidates should submit a curriculum vitae, a statement of interest, and three letters of recommendation to:
Scott A. Armstrong, M.D., Ph.D., Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute
David A. Williams, M.D., President, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Chief Scientific Officer, Boston Children’s Hospital
c/o Tara Roderick - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, 450 Brookline Avenue, Boston, MA 02215' firstname.lastname@example.org
We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law. Women and members of under-represented minorities are encouraged to apply.
Internal Number: PNO 5th attending
About Dana-Farber Cancer Institute
The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
Dana-Farber Cancer Institute's ultimate goal is the eradication of cancer, AIDS, and related diseases and the fear that they engender.
Above all else, we make a difference by relieving the burden of disease now and for the future through our research, clinical care, education, outreach and advocacy.
We pursue excellence relentlessly and with integrity in all that we do, adhering always to the highest standards of conduct.
Compassion and respect
For thos...e in our care and for one another.
We foster the spirit of inquiry, promoting collaboration and innovation across traditional boundaries while celebrating individual creativity.
BACK TO TOP
You are about to leave NRHA’s website and go to an external website.
Olorum, sequi ad magnati nvenist ibusciis aut rae. Eritect ibusandandem hilitiam imus por simolest, iscieni moloreped quamus, velesedi totatemodis del il il ium experum erestio. Nam que sandebit volorestium dolor si toriae.